MYLAN 2045 MYLAN 2045 (Tacrolimus 0.5 mg)
Pill with imprint MYLAN 2045 MYLAN 2045 is Orange / Gray, Capsule-shape and has been identified as Tacrolimus 0.5 mg. It is supplied by Mylan Pharmaceuticals Inc..
Tacrolimus is used in the treatment of organ transplant, rejection prophylaxis; organ transplant, rejection reversal and belongs to the drug class calcineurin inhibitors. Risk cannot be ruled out during pregnancy. Tacrolimus 0.5 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for MYLAN 2045 MYLAN 2045
Tacrolimus
- Imprint
- MYLAN 2045 MYLAN 2045
- Strength
- 0.5 mg
- Color
- Orange / Gray
- Size
- 14.00 mm
- Shape
- Capsule-shape
- Availability
- Prescription only
- Drug Class
- Calcineurin inhibitors
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Mylan Pharmaceuticals Inc.
- Inactive Ingredients
-
lactose anhydrous, ferrosoferric oxide, silicon dioxide, croscarmellose sodium, gelatin, hypromelloses, lactose monohydrate, magnesium stearate, sodium lauryl sulfate, titanium dioxide, ferric oxide yellow, D&C Red No. 28, D&C Yellow No. 10, FD&C Red No. 40, FD&C Blue No. 1, FD&C Blue No. 2, propylene glycol, shellac
Note: Inactive ingredients may vary.
Labelers / Repackagers
NDC Code | Labeler / Repackager |
---|---|
00378-2045 | Mylan Pharmaceuticals Inc. |
51079-0817 | UDL Laboratories Inc. |
More about tacrolimus
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 42 Reviews
- Drug class: calcineurin inhibitors
- FDA Alerts (1)
Consumer resources
- Tacrolimus oral and injection
- Tacrolimus Intravenous (Advanced Reading)
- Tacrolimus Oral, Intravenous (Advanced Reading)
- Tacrolimus Extended-Release Tablets
- Tacrolimus Capsules
- ... +3 more
Other brands: Prograf, Envarsus XR, Astagraf XL, Hecoria
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.